ResultsIQ

ResultsIQ › Latest results › Poly Medicure Limited

Poly Medicure Limited strategy deck summary

NSE: POLYMED · BSE: 531768

Strategy deck of 24 Sep 2025, summarised by AI from the filing.

Polymed to acquire Citieffe Group for ~Euro 23mn upfront, entering global orthopaedic Trauma & Extremities market.

Key takeaways

  1. Acquisition Polymed is acquiring 100% of Citieffe Group for equity valuation of ~Euro 18.8mn and total upfront payout of ~Euro 23mn.
  2. Guidance Transaction expected to be closed in next 4-8 weeks, funded by cash balances and internal accruals.
  3. Change Entry into global orthopaedic market through acquisition of Citieffe, a Trauma and Extremity fixation systems company.
  4. Driver Synergies from portfolio expansion, US expansion, Make in India, India expansion and distribution network.
  5. Risk Transaction closure subject to customary closing activities and closing adjustments.

Original filing on BSE

Poly Medicure Limited Q1 FY27 results

As filed: Revenue ₹525 cr (+30% year on year), EBITDA ₹125 cr (+18% year on year), PAT ₹85.3 cr (−8% year on year), EBITDA margin 23.8% (−249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹535 cr (+21% year on year), EBITDA ₹110 cr (−8% year on year), PAT ₹65.0 cr (−29% year on year), EBITDA margin 20.7% (−656 bps). Score 32 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 656 bps year on year. Profit fell 8% from last quarter. Revenue rose ₹93.5 cr on a year ago, more than the ₹63.0 cr it added the year before. Share price after the results: +6.7% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹494 cr (+16% year on year), EBITDA ₹111 cr (−3% year on year), PAT ₹70.8 cr (−17% year on year), EBITDA margin 22.5% (−460 bps). Score 14 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 460 bps year on year. Other income 27% of PBT. Profit fell 23% from last quarter. Profit rose ₹-14.2 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −10.6% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹444 cr (+6% year on year), EBITDA ₹115 cr (0% year on year), PAT ₹92.0 cr (+6% year on year), EBITDA margin 25.9% (−148 bps). Score 9 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 148 bps year on year. Other income 28% of PBT. Revenue rose ₹24.0 cr on a year ago, against ₹83.0 cr the year before. Share price after the results: −1.9% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹403 cr (+5% year on year), EBITDA ₹106 cr (+2% year on year), PAT ₹93.0 cr (+26% year on year), EBITDA margin 26.3% (−71 bps). Score 27 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 71 bps year on year. Other income 34% of PBT. Revenue fell 9% from last quarter. Revenue rose ₹18.0 cr on a year ago, against ₹64.0 cr the year before. Share price after the results: +5.5% in 28 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹441 cr (+17% year on year), EBITDA ₹120 cr (+25% year on year), PAT ₹92.0 cr (+35% year on year), EBITDA margin 27.2% (+181 bps). Score 70 of 100, Above trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 181 bps year on year. Revenue rose ₹63.0 cr on a year ago, against ₹71.0 cr the year before. Share price after the results: −19.6% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹424 cr (+25% year on year), EBITDA ₹115 cr (+29% year on year), PAT ₹85.0 cr (+31% year on year), EBITDA margin 27.1% (+95 bps). Score 69 of 100, Above trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 95 bps year on year. Revenue rose ₹84.0 cr on a year ago, more than the ₹55.0 cr it added the year before.
  • Q2 FY25: Revenue ₹420 cr (+25% year on year), EBITDA ₹115 cr (+37% year on year), PAT ₹87.0 cr (+40% year on year), EBITDA margin 27.4% (+246 bps). Score 81 of 100, Above trend. EBITDA margin rose 246 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Poly Medicure Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.